Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today that PDL Biopharma (“PDL”) has signed an agreement with Entelos to conduct in silico research and “virtual clinical trials”. The research is expected to take two months and is focused on identifying primary endpoints, patient types, and optimal doses to support one of PDL’s antibody development programs.

“We are pleased to add PDL to our growing list of biotechnology customers,” commented James Karis, president and CEO of Entelos. “Clinical trial simulations are one of the most powerful and important applications of our Physiolab platforms. Simulating clinical trials prior to conducting them can significantly reduce the risk, time, and overall cost of a drug program, especially when companies are faced with key decisions about selecting the right dose and patient types upfront. We look forward to making a positive impact at PDL and providing them useful information to support their pipeline.”

For further information please contact:

Entelos, Inc.

James Karis, President and CEO

Jill Fujisaki, VP Investor Relations
Tel: +1 650 572 5400

Evolution Securities

Bobbie Hilliam
Tel: +44 (0)20 7071 4300

Buchanan Communications

Lisa Baderoon / Mary-Jane Johnson
Tel +44 (0) 20 7466 5000

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, “virtual patients”, and toxicology reference systems to develop safer and more effective drugs and support pharmaceutical R&D and commercialization. In addition to internal drug programs in rheumatoid arthritis and women's health, Entelos provides customized technology and research services to global pharmaceutical and health-care companies in cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and skin sensitization. The company is also developing a model in oncology and is collaborating with the FDA to build a model of drug-induced liver injury. Entelos offers cost-effective drug development capabilities through its strategic alliance with India-based Jubilant Biosys.

Entelos is a registered trademark of Entelos, Inc. PhysioLab is a trademark and service mark of Entelos, Inc.
All other trademarks are the property of their registered owners.

  www.entelos.com